[6-K] ASCENTAGE PHARMA GROUP INTERNATIONAL Current Report (Foreign Issuer)

Ascentage Pharma Group International (AAPG) filed a Form 6-K that furnishes a press release titled “Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025.” The release is included as Exhibit 99.1.

Rhea-AI Filing Summary

Ascentage Pharma Group International (AAPG) filed a Form 6-K that furnishes a press release titled “Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025.” The release is included as Exhibit 99.1. The filing notes the company’s plan to engage investors at two conferences in November 2025 and provides the press release for additional details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/30/2025 - 08:30 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of October 2025

Commission File Number: 001-42484

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into English)

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

EXPLANATORY NOTE

On October 29, 2025, Ascentage Pharma Group International issued a press release entitled “Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025”. A copy of the press release is furnished as Exhibit 99.1 to this Report.

INDEX TO EXHIBITS

Exhibit
Number		Exhibit Title
99.1		Press Release dated October 29, 2025

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ASCENTAGE PHARMA GROUP INTERNATIONAL
Date: October 30, 2025	/s/ Dajun Yang
	Name:	Dajun Yang
	Title:	Chief Executive Officer

2